Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded at UBS Group

UBS Group upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a neutral rating to a buy rating in a research report report published on Monday, MarketBeat Ratings reports.

Several other brokerages have also recently issued reports on BAYRY. DZ Bank cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, February 23rd. Barclays raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, December 3rd. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Stock Down 3.2%

BAYRY stock opened at $11.14 on Monday. The firm’s 50-day moving average is $12.49 and its two-hundred day moving average is $10.08. The company has a market capitalization of $43.78 billion, a price-to-earnings ratio of -10.04 and a beta of 0.69. Bayer Aktiengesellschaft has a 52 week low of $5.30 and a 52 week high of $14.85. The company has a current ratio of 1.14, a quick ratio of 0.71 and a debt-to-equity ratio of 1.10.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.18. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.35%. The business had revenue of $13.24 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. On average, analysts forecast that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.